- $8.75m
- $6.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3 | ||
| Price to Tang. Book | 3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -547.72% | ||
| Return on Equity | -202.34% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 3rd, 2012
- Public Since
- June 30th, 2023
- No. of Shareholders
- 29
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 15,264,869
- Address
- 1 Enterprise Drive, Suite 430, SHELTON, 06484
- Web
- https://www.intensitytherapeutics.com
- Phone
- +1 2032217381
- Auditors
- EisnerAmper LLP
Upcoming Events for INTS
Similar to INTS
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 21:21 UTC, shares in Intensity Therapeutics are trading at $0.57. This share price information is delayed by 15 minutes.
Shares in Intensity Therapeutics last closed at $0.57 and the price had moved by -85.68% over the past 365 days. In terms of relative price strength the Intensity Therapeutics share price has underperformed the S&P500 Index by -87.09% over the past year.
The overall consensus recommendation for Intensity Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIntensity Therapeutics does not currently pay a dividend.
Intensity Therapeutics does not currently pay a dividend.
Intensity Therapeutics does not currently pay a dividend.
To buy shares in Intensity Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.57, shares in Intensity Therapeutics had a market capitalisation of $8.75m.
Here are the trading details for Intensity Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INTS
Based on an overall assessment of its quality, value and momentum Intensity Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Intensity Therapeutics is $9.30. That is 1523.32% above the last closing price of $0.57.
Analysts covering Intensity Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.84 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intensity Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -82.65%.
As of the last closing price of $0.57, shares in Intensity Therapeutics were trading -80.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Intensity Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Intensity Therapeutics' directors